|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | CD8+ T Lymphocytes Regulate the Arteriogenic Response to Ischemia by Infiltrating the Site of Collateral Vessel Development and Recruiting CD4+ Mononuclear Cells Through the Expression of Interleukin-16显示文摘 | Eugenio Stabile Timothy Kinnaird Andrea la Sala Sue Kim Hanson Craig Watkins Umberto Campia Matie Shou Stephan Zbinden Shmuel Fuchs Hardy Kornfeld Stephen E. Epstein Mary Susan Burnett | 2006 | Circulation2006，，1： | 1 |
| 2 | Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EFG,IGF-I,bFGF and PDGF-AB compared to controls显示文摘 | Miriam AM Susan BK FUNG LA | 2002 | Eur J Cell Biol2002，81，3： | 1 |
| 3 | IGF-I in epithelial ovarian cancer and its role in disease progression显示文摘 | Jane Brokaw Dionyssios Katsaros Andrew Wiley Lingeng Lu Dan Su Olga Sochirca Irene A. Rigault de la Longrais Susan Mayne Harvey Risch Herbert Yu | 2007 | Growth Factors2007，，5： | 1 |
| 4 | Oxidative stress,cell cycle,and neurodegeneration显示文摘 | Jeffrey AK Susan LA | 2003 | J Clin Inv2003，111，： | 1 |
| 5 | Valve-Sparing Aortic Root Replacement: Early and Midterm Outcomes in 83 Patients显示文摘 | Joseph S. Coselli Michael S. Hughes Susan Y. Green Matt D. Price Samantha Zarda Kim I. de la Cruz Ourania Preventza Scott A. LeMaire | 2014 | The Annals of Thoracic Surgery2014，，4： | 1 |
| 6 | Opsoclonus‐myoclonus and anti‐Hu positive limbic encephalitis in a patient with neuroblastoma显示文摘 | AndresMorales La Madrid Charles M.Rubin MichaelKohrman PeterPytel Susan L.Cohn | 2012 | Pediatr Blood Cancer2012，，3： | 1 |
| 7 | Applying the VAIC? model to Australian hotels显示文摘 | Gregory Laing Jillian Dunn Susan Hughes-Lucas | 2010 | Journal of Intellectual Capital2010，，3： | 1 |
| 8 | Experiential avoidance and emotion regulation difficukies in hoarding disorder 显示文摘 | Lorena FC Danielle LA Susan S | 2013 | Anxiety Disord2013，27，2： | 1 |
| 9 | Development of the Social Anxiety Scale for Children: Reliability and Concurrent Validity显示文摘 | Annette M. La Greca Susan Kraslow Dandes Patricia Wick Kimberly Shaw Wendy L. Stone | 1988 | Journal of Clinical Child & Adolescent Psychology1988，，1： | 1 |
| 10 | 显示文摘 | Susan LA Karen FK Attillo R | 1999 | Mol Med Today1999，5，： | 1 |
| 11 | MMTV-associated transcription factor binding sites increase nm23-H1 metastasis suppressor gene expression in human breast carcinoma cell lines显示文摘 | Taoufik Ouatas Susan E. Clare Melanie T. Hartsough Abel De La Rosa Patricia S. Steeg | 2002 | Clinical & Experimental Metastasis2002，，1： | 1 |
| 12 | BRCA1 promoter methylation is associated with increased mortality among women with breast Cancer显示文摘 | Garbowski XG Susan LA | 2009 | Breast Cancer Res Treat2009，115，2： | 1 |
| 13 | 降脂药物治疗病人需住院肌溶解症的发生率显示文摘背景:在美国降脂药物已获广泛应用。但是对各种降脂药物发生肌溶解症的危险性目前尚缺乏可靠的估计。
目的:对门诊情况下,不同他汀及贝特类药物(单用或联用)治疗病人肌溶解症的发生率进行估计。
设计、地点及病人:根据全美11个卫生保健计划申报数据建立不同他汀和贝特类用药起始队列。人选本队列的病例为1998年1月1H至2001年6月30日人组保健计划前至少用药180天的病人。人-时间按照单药治疗或他汀-贝特类联合治疗分类。
主要结局指标:每治疗10000人一年肌溶解症的发生率、所需治疗例数以及发生肌溶解症的相对危险性。
结果:在252460例采用降脂药物治疗的病人中,24例于治疗期间发生住院的肌溶解症。采用阿托伐他汀、普伐他汀或辛伐他汀单药治疗平均每10000人一年肌溶解症的发生率为0.44(95%可信区间[confidence interval,CI],0.20~0.84);西立伐汀为5.34(95%CI,1.46~13.68);贝特类为2.82(95%CI,0.58—8.24;P=0.056)。未用药者(unexposed person—time)肌溶解症的发生率为0(95%CI,0—0.48,P=0.56)。阿托伐他汀、普伐他汀与一种贝特联川肌溶解症的发生率增至5.98(95%CI,0.72~216.0),西立伐他汀与叭特类联用增至1035(95%CI,389—2117)。每治疗1年,发现1例肌溶解症的所需治疗例数他汀单药治疗为2272例,采用他汀和贝特类联合治疗的年龄较大的糖尿病人为484例,采用西立伐他汀加贝特类治疗的病人为9.7到12.7例。
结论:采用阿托伐他汀、普伐他汀及辛伐他汀单药治疗发生肌溶解症的危险相似而且很低;联合使用他汀及贝特类者危险增加,特别是在老年糖尿病病人。西立伐他汀联合贝特类每年治疗10例即可能有1例发生肌溶解症。 | David J, Graham Judy A , Staffa Deborah shatin Susan E. Andrade Stephanie D, Schech Lois La Grenade Jerry H. Gurwitz K. Arnold Chan Michael .J. Goodman Richard Platt 徐成斌(译) | 2006 | 美国医学会杂志(中文版)2006，25，1： | 0 |
| 14 | One year experience with computer-assisted propofol sedation for colonoscopy显示文摘AIM To report our one-year experience with computer assisted propofol sedation(CAPS) for colonoscopy as the first United States Medical Center to adopt CAPS technology for routine clinical use.METHODS Between September 2014 and August 2015, 2677 patients underwent elective outpatient colonoscopy with CAPS at our center. All colonoscopies were performed by 1 of 17 gastroenterologists certified in the use of the CAPS system, with the assistance of a specially trained nurse. Procedural success rates, polyp detection rates, procedure times and recovery times were recorded and compared against corresponding historical measuresfrom 2286 colonoscopies done with midazolam and fentanyl from September 2013 to August 2014. Adverse events in the CAPS group were recorded.RESULTS The mean age of the CAPS cohort was 59.9 years(48.7% male); 31.3% were ASA?Ⅰ, 67.3% ASA Ⅱ and 1.4% ASA Ⅲ. 45.1% of the colonoscopies were for screening, 31.5% for surveillance, and 23.4% for symptoms. The mean propofol dose administered was 250.7 mg(range 16-1470 mg), with a mean fentanyl dose of 34.1 mcg(0-100 mcg). The colonoscopy completion and polyp detection rates were similar to that of historical measures. Recovery times were markedly shorter(31 min vs 45.6 min, P < 0.001). In CAPS patients, there were 20(0.7%) cases of mild desaturation(< 90%) treated with a chin lift and reduction or temporary discontinuation of the propofol infusion, 21(0.8%) cases of asymptomatic hypotension(< 90 systolic blood pressure) treated with a reduction in the propofol rate, 4(0.1%) cases of marked agitation or discomfort due to undersedation, and 2 cases of pronounced transient desaturation requiring brief(< 1 min) mask ventilation. There were no sedation-related serious adverse events such as emergent intubation, unanticipated hospitalization or permanent injury. CONCLUSION CAPS appears to be a safe, effective and efficient means of providing moderate sedation for colonoscopy in relatively healthy patients. Recovery times were much shorter than historical measures. There were few adverse events, and no serious adverse events, related to CAPS. | Otto S Lin Danielle La Selva Richard A Kozarek Deborah Tombs Wade Weigel Ryan Beecher Johannes Koch Susan Mc Cormick Michael Chiorean Fred Drennan Michael Gluck Nanda Venu Michael Larsen Andrew Ross | 2017 | World Journal of Gastroenterology2017，23，16： | 0 |
| 15 | A comprehensive review of genetic causes of obesity显示文摘Background Obesity is a multifactorial chronic disease with a high,increasing worldwide prevalence.Genetic causes account for 7%of the cases in children with extreme obesity.Data sources This narrative review was conducted by searching for papers published in the PubMed/MEDLINE,Embase and SciELO databases and included 161 articles.The search used the following search terms:'obesity','obesity and genetics','leptin','Prader-Willi syndrome',and'melanocortins'.The types of studies included were systematic reviews,clinical trials,prospective cohort studies,cross-sectional and prospective studies,narrative reviews,and case reports.Results The leptin-melanocortin pathway is primarily responsible for the regulation of appetite and body weight.However,several important aspects of the pathophysiology of obesity remain unknown.Genetic causes of obesity can be grouped into syndromic,monogenic,and polygenic causes and should be assessed in children with extreme obesity before the age of 5 years,hyperphagia,or a family history of extreme obesity.A microarray study,an analysis of the melanocortin type 4 receptor gene mutations and leptin levels should be performed for this purpose.There are three therapeutic levels:lifestyle modifications,pharmacological treatment,and bariatric surgery.Conclusions Genetic study technologies are in constant development;however,we are still far from having a personalized approach to genetic causes of obesity.A significant proportion of the affected individuals are associated with genetic causes;however,there are still barriers to its approach,as it continues to be underdiagnosed. | Marcio Jose Concepcion-Zavaleta Juan Eduardo Quiroz-Aldave Maria del Carmen Durand-Vasquez Elman Rolando Gamarra-Osorio Juan del Carmen Valencia de la Cruz Claudia Mercedes Barrueto-Callirgos Susan Luciana Puelles-Leon Elena de Jesus Alvarado-Leon Frans Leiva-Cabrera Francisca Elena Zavaleta-Gutierrez Luis Alberto Concepcion-Urteaga Jose Paz-Ibarra | 2024 | World Journal of Pediatrics2024，20，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员